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Introduction
Orphanin FQ (OFQ) is a heptadecapeptide that is an endogenous ligand for orphan opioid receptor-like (ORL1) receptors (Mollereau et al., 1994; Meunier et al., 1995; Reinscheid et al., 1995) . The ORL1 receptor is highly homologous with classical opioid receptors, particularly in its transmembrane and intracellular domains. Unlike opioid receptors, the ORL1 receptor does not bind opioid ligands with high anity. For example, classical opioid receptor agonists and antagonists, such as morphine and naloxone, are not active on the ORL1 receptor (see reviews, 'Henderson & McKnight, 1997; Darland et al., 1998; Calo et al., 2000) . Although the actions of OFQ have much in common with those of opioid peptides at the cellular level, functional studies suggest high degree of complexity. Pharmacological studies in rodent species have shown a dual activity of OFQ (i.e., both pronociceptive and antinociceptive actions) in pain modulation, depending on several factors including administration routes, dose ranges and nociceptive assays (Calo et al., 2000) . However, it is unknown whether activation of ORL1 receptors by OFQ in primates produces pronociceptive or antinociceptive eects.
OFQ inhibits cyclic AMP accumulation (Meunier et al., 1995; Reinscheid et al., 1995) , inhibits Ca 2+ entry through voltage-dependent Ca 2+ channels (Connor et al., 1996; British Journal of Pharmacology (2002) Kno¯ach et al., 1996) , and increases K + conductance in neurons (Vaughan & Christie, 1996; Jennings, 2001 ). In addition, it has been shown that OFQ inhibits the release of pronociceptive substances such as substance P (SP) and calcitonin gene-related peptide (CGRP) from peripheral sensory nerves (Giuliani & Maggi, 1996; . These in vitro studies seem to support the inhibitory function of the ORL1 receptor in the nociception-relevant processes.
Capsaicin, the pungent ingredient in hot chili peppers, has been used to evoke nociception for evaluating potential antinociceptive agents in monkeys and humans (Eisenach et al., 1997; Ko et al., 1998) . Exposure of primary aerent nociceptors to capsaicin leads to excitation of the neuron and local release of in¯ammatory pain mediators such as SP and CGRP (see reviews, Winter et al., 1995; Szallasi & Blumberg, 1999) . It has been reported that intradermal administration of capsaicin to human skin produces burning pain and allodynic/hyperalgesic responses (Simone et al., 1989; Lamotte et al., 1992) . We also found that s.c. administration of capsaicin in the monkey's tail evoked a nociceptive response, thermal allodynia/hyperalgesia, which was manifested as a reduced tail-withdrawal latency in normally innocuous warm water (Ko et al., 1998) . In this procedure, s.c. administration of small, systemically inactive doses of mu opioid receptor (mOR) agonists or kappa opioid receptor (kOR) agonists in the tail can attenuate capsaicin-induced thermal nociception. This local antinociception has been demonstrated as the function of peripheral opioid receptors and it can be pharmacologically separated from the central action of opioids (Ko et al., 1998; 1999a, b) . More importantly, this capsaicin-induced pain model in monkeys provides a useful tool to study the peripheral antinociception of novel agents, which may have the therapeutic potential in humans.
The aim of this study was therefore to examine whether local administration of OFQ can attenuate capsaicin-induced nociception in monkeys. Antagonist studies were performed to con®rm whether the ORL1 receptor mediates the peripheral action of OFQ by using a selective ORL1 receptor antagonist, J-113397 (Kawamoto et al., 1999; Ozaki et al., 2000) . In addition, selective opioid agonists and antagonists were used in this procedure to evaluate whether the function of peripheral ORL1 receptors is independent of classical opioid receptors.
Methods

Subjects
Six adult male and female rhesus monkeys (Macaca mulatta) with body weights ranging between 7.6 and 12.9 kg were used (their mean weight during this study was 9.8 kg). Individual weight did not signi®cantly change throughout the entire study. They were housed individually with free access to water and were fed approximately 25 ± 30 biscuits (Purina Monkey Chow; Ralston Purina Co., St. Louis, MO, U.S.A.) and fresh fruit daily. All monkeys were previously trained in the warm water tail-withdrawal procedure and they did not have exposure to any drug including opioids or capsaicin for one month before the present study. Animals used in this study were maintained in accordance with the University Committee on the Use and Care of Animals in the University of Michigan, and the Guide for the Care and Use of Laboratory Animals (7th edn) by the Institute of Laboratory Animal Resources (Natl. Acad. Press, Washington DC, revised 1996) .
Procedure
Nociceptive responses to thermal stimuli were measured by a warm water tail-withdrawal procedure which has been described previously (Ko et al., 1998) . Brie¯y, monkeys were seated in restraint chairs and the lower part of the shaved tail, approximately 15 cm, was immersed into warm water maintained at temperatures of 42, 46, or 508C. Tail-withdrawal latencies were measured by an experimenter who did not know the experimental conditions. A maximum cuto latency, 20 s, was used. Each experimental session began with control determinations at three temperatures in a varying order. Subsequent tail-withdrawal latencies were determined at 5, 15, 30, 45, and 60 min after the drug injection. A single dosing procedure was used in all test sessions. All six monkeys were used in each experimental session which was conducted once per 10 days.
Experimental design
After capsaicin was administered subcutaneously in the tail, it dose-dependently caused thermal nociception. This thermal nociception, allodynic/hyperalgesic response, was manifested as a reduced tail-withdrawal latency, from a maximum value of 20 s to approximately 2 ± 3 s, in 468C water at 15 min after injection. The 15 min time point was the time of peak eects of capsaicin because there was no temperature-and capsaicin dose-dependency at the 5 min time point and there was a lesser degree of capsaicin eects at the 30 min and remaining time points (Ko et al., 1998) . In addition, 468C water was chosen because there was a lesser degree of thermal allodynia/hyperalgesia in 428C water and it was not possible to study hyperalgesic responses in 508C water after capsaicin (Ko et al., 1998) . Based on these previous results, we choose 100 mg of capsaicin in 468C water as a standard noxious stimulus to evoke thermal allodynia/hyperalgesia for the present study.
Antinociceptive effects of orphanin FQ
OFQ (1 ± 30 mg) was co-administered with capsaicin in the tail to evaluate its antinociceptive eect. After the doseresponse study, the maximum locally eective dose was administered subcutaneously in the back (i.e., around the scapular region), in order to verify the local action of OFQ. In addition, this locally eective dose was administered subcutaneously in the tail alone to evaluate whether it changed the thermal nociceptive threshold in the absence of capsaicin.
Antagonism of peripheral ORL1 receptors
Considering that onset and distribution factors may be minimized with local administration, J-113397 (1 ± 10 mg), a selective ORL1 receptor antagonist, was co-administered with capsaicin and OFQ in the tail to evaluate its local antagonist eect. Similarly, the maximum locally eective dose of J-113397 was injected subcutaneously in the back to verify whether its ORL1 receptor antagonism was localized in the tail. The locally eective dose of J-113397 was also administered in the tail alone to detect whether it changed the thermal nociceptive threshold of the monkey's tail.
In addition, three opioid receptor antagonists, quadazocine, nor-binaltorphimine (nor-BNI), and naltrindole, which are selective for mOR, kOR, and dOR, respectively, were used to con®rm the receptor selectivity of OFQ (30 mg)-induced local antinociception. It has been demonstrated that 10 mg of quadazocine and 320 mg of nor-BNI signi®cantly antagonized mOR agonist-and kOR agonist-induced local antinociception respectively in our previous studies (Ko et al., 1998; 1999a; . We previously found that local administration of BW373U86, a selective dOR agonist, in the tail did not attenuate capsaicin-induced thermal nociception (unpublished data). Thus, it is dicult to determine the locally active dose of naltrindole in the monkey's tail. The large dose of naltrindole 320 mg was chosen based on its systemically active dose, 1 mg kg 71 , in monkeys (Butelman et al., 1995) . This dose for local injection in the tail was approximately 30 fold lower than systemic dose in the monkeys weighing 10 kg. Furthermore, three opioid receptor agonists, DAMGO, U50488 and BW373U86, which are selective for mOR, kOR, and dOR, respectively, were used to verify the ORL1 receptor antagonism selectivity of J-113397. In previous studies, it has been demonstrated that 32 mg of DAMGO and 100 mg of U50488 signi®cantly attenuated capsaicin (100 mg)-induced thermal nociception through peripheral mOR and kOR, respectively (Ko et al., 1998; 1999a, b) . By using the same procedure, 10 mg of J-113397 was coadministered with capsaicin and one opioid receptor agonist in the tail to verify whether J-113397 interfered with the local actions of dierent types of opioid receptor agonists.
Data analysis
Individual tail-withdrawal latencies were converted to per cent of maximum possible eect (%MPE) by the following formula: %MPE=[(test latency7control latency) / (cuto latency, 20 s7control latency)] 6100, in order to calculate ED 50 values. The 15 min time point was used for data analysis because this was the time of peak eects of capsaicin and peptidic opioid agonists following local administration (Ko et al., 1998; 1999a; . Mean ED 50 values were obtained from individual ED 50 values, which were calculated by least-squares regression using the portion of the doseeect curves spanning 50% MPE, and 95% con®dence limits were also determined. In addition, signi®cant dierences of tail-withdrawal latencies between dosing conditions were analysed with one-way ANOVA followed by the Newman ± Keuls test (P5.01). 
Results
Monkeys used in this study displayed a consistent pro®le in tail-withdrawal responses. They kept their tails in 42 and 468C water for 20 s (cuto latency) and removed their tails Figure 1 Time course of capsaicin-induced thermal nociception, allodynia/hyperalgesia, in monkeys. Each panel represents the time course of capsaicin eect on the tail-withdrawal latency in dierent degrees of water. All points represent the mean+s.e.m. (n=6). Before injection, the tail-withdrawal latencies were determined. Either capsaicin 100 mg or vehicle solution was injected subcutaneously in the tail with constant 0.1 ml volume at`0' time point. 3 s) . After capsaicin 100 mg was injected subcutaneously in the tail, it evoked a nociceptive response, thermal allodynia/hyperalgesia, which was manifested as a reduced tail-withdrawal latency in 468C water. This thermal nociceptive response started at 5 min, continued until 15 min, and then gradually disappeared within an hour after injection (see Figure 1 , middle panel). These responses were similar to those we have reported previously in dierent groups of monkeys (Ko et al., 1998; 1999a; . Figure 2 illustrates the antinociceptive eect of OFQ against capsaicin-induced thermal nociception following s.c. administration in the tail. Co-administration of OFQ (1 ± 30 mg) with capsaicin (100 mg) in the tail dose-dependently attenuated capsaicin-induced thermal nociception in 468C water. However, when the locally eective dose of OFQ 30 mg was administered subcutaneously in the back, it was not eective against capsaicin. The ED 50 value of OFQ-induced local antinociception in this procedure was 6.3 mg (95% C.L.: 3.6 ± 11.1 mg). It is worth noting that s.c. administration of OFQ in the tail and in the back at these doses did not cause any notable behavioral changes, such as sedation or agitation. Figure 3 illustrates the peripheral ORL1 receptor antagonism of OFQ-induced local antinociception by J-113397 in the tail. Co-administration of J-113397 (1 ± 10 mg) with capsaicin (100 mg) and OFQ (30 mg) in the tail dose-dependently antagonized the inhibitory action of OFQ in capsaicininduced nociception in 468C water. However, when the locally eective dose of J-113397, 10 mg, was administered Figure 4 illustrates tail-withdrawal responses of naõÈ ve monkeys at 15 min following local injection in the tail. The injection procedure itself (i.e., vehicle injection) did not interfere with normal tail-withdrawal responses of monkeys. Although 508C water alone is a noxious stimulus, s.c. administration of OFQ 30 mg in the tail did not produce antinociception against 508C water in this procedure ( Figure  4, upper panel) . Both OFQ (1 ± 30 mg) and J-113397 (1 ± 10 mg) alone did not cause any swelling in the tail and both agents did not alter the thermal nociceptive threshold of naõÈ ve monkeys. In order to detect whether OFQ produces a dual action (i.e., both pronociception and antinociception) across a wide dose range, from 1 pg to 1 mg of OFQ was further tested alone in the monkey's tail. We did not ®nd any changes of tail-withdrawal latencies in 42, 46 and 508C warm water following local injection of OFQ in the tail (data not shown). It should be noted that neither s.c. OFQ nor s.c. J-113397 in the tail changed tail-withdrawal latencies through the entire test session (i.e., 5 ± 60 min) after local injection. Figure 5 illustrates the antagonist eect of dierent opioid receptor antagonists against OFQ-induced local attenuation of capsaicin-induced thermal nociception in 468C water. The local antinociceptive action of OFQ was only antagonized signi®cantly by J-113397 (10 mg). Local administration of quadazocine (32 mg, selective for mOR), nor-BNI (320 mg, selective for kOR), or naltrindole (320 mg, selective for dOR) was not eective in reversing the inhibitory action of OFQ in the periphery. On the other hand, Figure 6 illustrates the antagonist eect of J-113397 against dierent opioid receptor agonist-induced local actions. Local administration of DAMGO, a selective mOR agonist, or U50488, a selective kOR agonist, but not BW373U86, a selective dOR agonist, produced profound attenuation of capsaicin-induced thermal nociception. However, local administration of J-113397 (10 mg) did not signi®cantly antagonize the antinociceptive action mediated by either peripheral mOR or kOR.
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Discussion
This study demonstrated that local administration of OFQ in the monkey's tail attenuated capsaicin-induced thermal nociception. OFQ-induced local antinociception was mediated by peripheral ORL1 receptors, independently of the classical opioid receptors. These data provide the ®rst functional evidence of selective ORL1 receptor-mediated actions of OFQ in a primate species.
Antinociceptive effects of orphanin FQ
This study clearly shows that local administration of OFQ can dose-dependently inhibit capsaicin-induced thermal nociception in monkeys (Figure 2) . The locally eective dose of OFQ, when applied in the back, did not inhibit capsaicininduced nociception. This indicates that the site of action of locally administered OFQ is located in the tail. Local administration of peptides can minimize the distribution factors and adverse eects produced by central or systemic administration. In particular, the site of action can be isolated and studied in the periphery. It has been shown that opioid peptides such as DAMGO and dynorphin-related analogues are only eective following local administration to attenuate capsaicin-induced nociception; and they are not eective following systemic administration even at doses up to 1000-fold of locally eective doses. Such a large dierence in potency is only observed with peptidic ligands, but not with non-peptidic compounds (Ko et al., 1998; 1999a; . These studies strengthen the notion that local application of peptidic ligands without untoward side eects may be a useful medication for localized painful conditions.
It should be noted that local administration of OFQ alone did not modify the thermal nociceptive threshold of the monkey's tail (Figure 4, upper panel) . OFQ-induced local antinociception was only observed under the allodynia-or hyperalgesia-like state. This observation is similar to ®ndings from our previous studies which characterized local antinociceptive actions of mOR and kOR agonists against capsaicin (Ko et al., 1998; 1999a) and it is also similar to ®ndings from rodent studies, in which the antinociceptive potency of opioid receptor agonists is enhanced on the peripheral terminals of nociceptive primary aerents innervating in¯amed tissues (e.g., Stein et al., 1989; Nagasaka et al., 1996) . There are several factors that may account for this phenomenon. For example, in¯ammation produces disruption of perineurial barriers, which leads to an easier access of opioid ligands to peripheral opioid receptors (Antonijevic et al., 1995) . Opioid receptor agonists do not suppress the discharge of nociceptors in normal skin or their responses to noxious stimuli (Raja et al., 1986; Senami et al., 1986) . Interestingly, Honore et al. (1996) have shown that intraplantar morphine depresses spinal c-Fos expression which is induced by carrageenan in¯ammation, but not by noxious heat. The ORL1 receptor may have a similar function as classical opioid receptors to modulate the activity of peripheral sensory ®bers which are dynamically regulated by a variety of neuromediators following tissue injury and in¯ammation.
Capsaicin evokes pain sensation by activating the vanilloid receptor (VR1) and stimulating the release of neuropeptides such as SP and CGRP from primary aerent nociceptors (Winter et al., 1995; Caterina et al., 1997; Szallasi & Blumberg, 1999) . Activation of peripheral mOR, kOR, or ORL1 receptors, but not dOR, attenuates capsaicin-induced thermal nociception in monkeys (Ko et al., 1998; 1999a; and present study) . This local antinociception against capsaicin can be explained by both inhibition of the excitability of sensitized nociceptors (Russell et al., 1987; Haley et al., 1990; Andreev et al., 1994) and inhibition of the release of SP and CGRP from peripheral sensory endings (Yonehara et al., 1992; Giuliani & Maggi, 1996; Helyes et al., 1997) . However, the rapid time course of capsaicin-induced thermal nociception may suggest that peripheral peptide release is not a major contributor to allodynia/hyperalgesia in this study and the nociception is due to the direct eect of capsaicin on the nerve terminals. Nevertheless, it would be important for further in vitro studies to compare the dierential ability of mOR, kOR, dOR, and ORL1 receptors in a primate species in terms of inhibiting the discharge of primary aerent nociceptors and inhibiting the release of pronociceptive substances associated with neurogenic in¯ammation. Studies in mice lacking VR1 have demonstrated that VR1 is required for in¯ammatory sensitization to noxious thermal stimuli and VR1 is essential for tissue injury-induced thermal hyperalgesia (Caterina et al., 2000; Davis et al., 2000) . Considering that capsaicin-sensitive nerve ®bres are involved in a variety of nociceptive conditions (BarthoÂ et al., 1990; Kim et al., 1995; Winter et al., 1995; Szallasi & Blumberg, 1999) , local administration of ORL1 receptor agonists may be eective for reducing pain derived from dierent nociceptive origins.
Antagonism of peripheral ORL1 receptors
Local administration of J-113397, a selective ORL1 receptor antagonist, dose-dependently antagonized local antinociception of OFQ (Figure 3) . In addition, a locally eective dose of J-113397, when administered subcutaneously in the back, did not antagonize the local action of OFQ. These antagonism studies con®rm the site of action of locally administered OFQ, indicating that peripheral ORL1 receptors mediate local antinociception of OFQ against capsaicininduced thermal nociception. As noted, local administration of J-113397 alone did not modify the thermal nociceptive threshold of the monkey's tail (Figure 4, bottom panel) . This may suggest that tonic activity of peripheral ORL1 receptors does not have a major role in modulating local nociceptive responses. Further studies utilizing systemic or central administration of ORL1 receptor antagonists, including insurmountable antagonists, will be necessary to determine the tonic activity of central ORL1 receptors.
Local administration of opioid receptor antagonists selective for mOR, kOR, and dOR did not antagonize the local antinociceptive action of OFQ ( Figure 5 ). This observation strongly supports that peripheral ORL1 receptors selectively mediate local antinociceptive eects of OFQ in this procedure. In addition, local administration of J-113397 did not antagonize the local antinociceptive actions of mOR and kOR agonists in this procedure (Figure 6 ). It further con®rms the antagonist selectivity of J-113397 on the ORL1 receptor (Ozaki et al., 2000; Hashiba et al., 2001) . Taken together, these behavioral studies provide functional evidence that the ORL1 receptor, independent of classical opioid receptors, plays an important role in modulation of peripheral sensory nerves following tissue injury or in¯ammation.
General summary
This study clearly demonstrates that peripheral ORL1 receptors mediate OFQ-induced local antinociception against capsaicininduced thermal nociception in monkeys. More importantly, it provides a pharmacological basis for further studying the function of the ORL1 receptor in primates. The ORL1 receptor is widely distributed in the central and peripheral nervous systems and it may have very important roles in a variety of physiological functions (Henderson & McKnight, 1997; Darland et al., 1998; Calo et al., 2000) . Recently, a selective nonpeptidic ORL1 agonist, Ro 64-6198, has been developed (Dautzenberg et al., 2001) . This non-peptidic ORL1 agonist can be further studied in monkeys in order to elucidate the potential antinociceptive function of the ORL1 receptor in primates. In particular, both intravenous and intrathecal administration routes are widely used for analgesic delivery in the clinic. Future studies characterizing and comparing the behavioral eects of i.v. and i.t. administration of OFQ and nonpeptidic ORL1 agonists in monkeys would provide a great deal of information for potential pain management in humans.
